Industry
Flerie takes a different approach to investing in biotechnology - Ted Fjällman, CEO of investment company Flerie, talks about the biotechnology investment firm's strategy
Yilmaz Biter
Yilmaz Biter is a business and technology writer, as well as an M&A lawyer. Through his first company, Tekstbureau Biter, he connected complex industries with accessible storytelling. His work has appeared in Business Insider, BiotechNEWS & Life Sciences, Quote (the Dutch equivalent of Forbes), MenA.nl, and Elsevier Weekblad, where he has covered, among others, the dynamic intersection of venture capital, entrepreneurship, and biotechnology. In his latest venture, BioPitch, Yilmaz is focusing on uncovering untold stories within the life sciences sector, with the aim of bridging the gap between scientific innovation and the capital that fuels it.
Yilmaz Biter is a business and technology writer, as well as an M&A lawyer. Through his first company, Tekstbureau Biter, he connected complex industries with accessible storytelling. His work has appeared in Business Insider, BiotechNEWS & Life Sciences, Quote (the Dutch equivalent of Forbes), MenA.nl, and Elsevier Weekblad, where he has covered, among others, the dynamic intersection of venture capital, entrepreneurship, and biotechnology. In his latest venture, BioPitch, Yilmaz is focusing on uncovering untold stories within the life sciences sector, with the aim of bridging the gap between scientific innovation and the capital that fuels it.
Yilmaz Biter is a business and technology writer, as well as an M&A lawyer. Through his first company, Tekstbureau Biter, he connected complex industries with accessible storytelling. His work has appeared in Business Insider, BiotechNEWS & Life Sciences, Quote (the Dutch equivalent of Forbes), MenA.nl, and Elsevier Weekblad, where he has covered, among others, the dynamic intersection of venture capital, entrepreneurship, and biotechnology. In his latest venture, BioPitch, Yilmaz is focusing on uncovering untold stories within the life sciences sector, with the aim of bridging the gap between scientific innovation and the capital that fuels it.
